TNXP Relative Valuation
TNXP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TNXP is overvalued; if below, it's undervalued.
Historical Valuation
Tonix Pharmaceuticals Holding Corp (TNXP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.64 is considered Undervalued compared with the five-year average of -1.29. The fair price of Tonix Pharmaceuticals Holding Corp (TNXP) is between 19.03 to 68.10 according to relative valuation methord. Compared to the current price of 15.63 USD , Tonix Pharmaceuticals Holding Corp is Undervalued By 17.85%.
Relative Value
Fair Zone
19.03-68.10
Current Price：15.63
17.85%
Undervalued
-1.67
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Tonix Pharmaceuticals Holding Corp. (TNXP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.95. The thresholds are as follows: Strongly Undervalued below -17.40, Undervalued between -17.40 and -9.68, Fairly Valued between 5.77 and -9.68, Overvalued between 5.77 and 13.50, and Strongly Overvalued above 13.50. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.04
EV/EBIT
Tonix Pharmaceuticals Holding Corp. (TNXP) has a current EV/EBIT of -0.04. The 5-year average EV/EBIT is -0.36. The thresholds are as follows: Strongly Undervalued below -2.78, Undervalued between -2.78 and -1.57, Fairly Valued between 0.85 and -1.57, Overvalued between 0.85 and 2.06, and Strongly Overvalued above 2.06. The current Forward EV/EBIT of -0.04 falls within the Historic Trend Line -Fairly Valued range.
1.64
PS
Tonix Pharmaceuticals Holding Corp. (TNXP) has a current PS of 1.64. The 5-year average PS is 1.67. The thresholds are as follows: Strongly Undervalued below -3.27, Undervalued between -3.27 and -0.80, Fairly Valued between 4.14 and -0.80, Overvalued between 4.14 and 6.61, and Strongly Overvalued above 6.61. The current Forward PS of 1.64 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Tonix Pharmaceuticals Holding Corp. (TNXP) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.72. The thresholds are as follows: Strongly Undervalued below -27.12, Undervalued between -27.12 and -14.92, Fairly Valued between 9.47 and -14.92, Overvalued between 9.47 and 21.67, and Strongly Overvalued above 21.67. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Tonix Pharmaceuticals Holding Corp. (TNXP) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.62. The thresholds are as follows: Strongly Undervalued below -23.34, Undervalued between -23.34 and -12.48, Fairly Valued between 9.24 and -12.48, Overvalued between 9.24 and 20.09, and Strongly Overvalued above 20.09. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Tonix Pharmaceuticals Holding Corp (TNXP) has a current Price-to-Book (P/B) ratio of 0.73. Compared to its 3-year average P/B ratio of 0.43 , the current P/B ratio is approximately 69.60% higher. Relative to its 5-year average P/B ratio of 0.68, the current P/B ratio is about 7.49% higher. Tonix Pharmaceuticals Holding Corp (TNXP) has a Forward Free Cash Flow (FCF) yield of approximately -39.16%. Compared to its 3-year average FCF yield of -456.96%, the current FCF yield is approximately -91.43% lower. Relative to its 5-year average FCF yield of -351.87% , the current FCF yield is about -88.87% lower.
0.73
P/B
Median3y
0.43
Median5y
0.68
-39.16
FCF Yield
Median3y
-456.96
Median5y
-351.87
Competitors Valuation Multiple
The average P/S ratio for TNXP's competitors is 3.07, providing a benchmark for relative valuation. Tonix Pharmaceuticals Holding Corp Corp (TNXP) exhibits a P/S ratio of 1.64, which is -46.7% above the industry average. Given its robust revenue growth of 16.58%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TNXP decreased by 63.49% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -503.65 to -972.95.
The secondary factor is the Revenue Growth, contributed 16.58%to the performance.
Overall, the performance of TNXP in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
KTCC
Key Tronic Corp
2.69USD
-0.74%
VNCE
Vince Holding Corp
3.82USD
-5.45%
OPXS
Optex Systems Holdings Inc
13.31USD
-0.30%
SER
Serina Therapeutics Inc
2.42USD
16.35%
ATNM
Actinium Pharmaceuticals Inc
1.46USD
2.10%
DWSN
Dawson Geophysical Co
1.72USD
2.38%
RFIL
RF Industries Ltd
6.01USD
4.07%
SGRP
SPAR Group Inc
0.9001USD
-1.10%
ESLA
Estrella Immunopharma Inc
1.44USD
5.11%
Frequently Asked Questions
Is Tonix Pharmaceuticals Holding Corp (TNXP) currently overvalued or undervalued?
Tonix Pharmaceuticals Holding Corp (TNXP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.64 is considered Undervalued compared with the five-year average of -1.29. The fair price of Tonix Pharmaceuticals Holding Corp (TNXP) is between 19.03 to 68.10 according to relative valuation methord. Compared to the current price of 15.63 USD , Tonix Pharmaceuticals Holding Corp is Undervalued By 17.85% .
What is Tonix Pharmaceuticals Holding Corp (TNXP) fair value?
TNXP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Tonix Pharmaceuticals Holding Corp (TNXP) is between 19.03 to 68.10 according to relative valuation methord.
How does TNXP's valuation metrics compare to the industry average?
The average P/S ratio for TNXP's competitors is 3.07, providing a benchmark for relative valuation. Tonix Pharmaceuticals Holding Corp Corp (TNXP) exhibits a P/S ratio of 1.64, which is -46.70% above the industry average. Given its robust revenue growth of 16.58%, this premium appears unsustainable.
What is the current P/B ratio for Tonix Pharmaceuticals Holding Corp (TNXP) as of Jan 08 2026?
As of Jan 08 2026, Tonix Pharmaceuticals Holding Corp (TNXP) has a P/B ratio of 0.73. This indicates that the market values TNXP at 0.73 times its book value.
What is the current FCF Yield for Tonix Pharmaceuticals Holding Corp (TNXP) as of Jan 08 2026?
As of Jan 08 2026, Tonix Pharmaceuticals Holding Corp (TNXP) has a FCF Yield of -39.16%. This means that for every dollar of Tonix Pharmaceuticals Holding Corp’s market capitalization, the company generates -39.16 cents in free cash flow.
What is the current Forward P/E ratio for Tonix Pharmaceuticals Holding Corp (TNXP) as of Jan 08 2026?
As of Jan 08 2026, Tonix Pharmaceuticals Holding Corp (TNXP) has a Forward P/E ratio of -1.67. This means the market is willing to pay $-1.67 for every dollar of Tonix Pharmaceuticals Holding Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Tonix Pharmaceuticals Holding Corp (TNXP) as of Jan 08 2026?
As of Jan 08 2026, Tonix Pharmaceuticals Holding Corp (TNXP) has a Forward P/S ratio of 1.64. This means the market is valuing TNXP at $1.64 for every dollar of expected revenue over the next 12 months.